Nanoparticles of cerium oxide targeted to an amyloid-beta antigen of Alzheimer's disease and associated methods

• US 8,877,207 B2
• Filed: 07/18/2011
• Issued: 11/04/2014
• Est. Priority Date: 09/17/2010
• Status: Active Grant

• Current Assignee: University Of L'Aquila
• Original Assignee: University of Central Florida Research Foundation Inc. (State University System of Florida), University Of L'Aquila
• Inventors: Cimini, Annamaria, D'Angelo, Barbara, Das, Soumen, Seal, Sudipta
• Primary Examiner(s): Emch, Gregory S
• Assistant Examiner(s): Weidner, Adam M
• Application Number:
  US13/184,660
• Publication Number:
  US 20120070500A1
• Time in Patent Office: 1,205 Days
• US Class Current: 424/194.1
• CPC Class Codes: A61K 33/244 Lanthanides; Compounds thereof medicinal preparations containing radioactive lanthanides for use in therapy or testing in vivo A61K51/00
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 47/6843 the antibody targeting a material from animals or humans
• CPC Class Codes: A61K 47/6923 the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
• CPC Class Codes: A61K 47/6935 the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

Disclosed is a composition immunologically targeted to Alzheimer'"'"'s disease (AD), the composition containing amine functionalized nanoparticles of Cerium oxide coated with polyethylene glycol and bearing an antibody specific for an amyloid-beta antigen associated with AD. The invention also includes a medication manufactured with the targeted nanoceria particles and methods of treatment by administering the targeted nanoceria particles to patients in need thereof.

Claims

1. A composition comprising polyethylene glycol (PEG) coated nanoparticles of Cerium oxide having an antibody bound thereto, the antibody being specific for an antigen associated with a predetermined disease condition, wherein the PEG comprises a bifunctional molecule comprising a carboxy terminal and amine terminal, the carboxy terminal being connected to an amine group on the nanoparticles and an amine terminal being connected to the antibody as follows:

CeO₂—

NHCO—

[CH₂CH₂O]ⁿ—

CH₂CH₂NH-antibody.

2. The composition of claim 1, wherein said nanoparticles are amine functionalized to promote coating by the PEG.

3. The composition of claim 1, wherein said antibody is specifically targeted against an amyloid-beta antigen associated with a neurodegenerative disease.

4. The composition of claim 1, wherein the nanoparticles are approximately from 3-5 nm in size prior to coating with PEG.

5. The composition of claim 1, contained in a manufactured medication biologically acceptable for administration to a patient exhibiting symptoms of the predetermined disease.

6. A composition specifically targeted to a neurodegenerative disease, said composition comprising amine functionalized nanoparticles of Cerium oxide coated with polyethylene glycol and bearing an antibody specific for an antigen associated with the neurodegenerative disease;

wherein the PEG comprises a bifunctional molecule comprising a carboxy terminal and amine terminal, the carboxy terminal being connected to an amine group on the nanoparticles and an amine terminal being connected to the antibody as follows;

CeO₂—

NHCO—

[CH₂CH₂O]_n—

CH₂CH₂NH-antibody.

7. The composition of claim 6, contained in a manufactured medication biologically acceptable for administration to a patient exhibiting symptoms of the neurodegenerative disease.

8. A method of treatment for a neurodegenerative disease, the method comprising administering the composition of claim 6 to a patient in need thereof.

9. A composition immunologically targeted to Alzheimer'"'"'s disease (AD), said composition comprising amine functionalized nanoparticles of Cerium oxide coated with polyethylene glycol and bearing an antibody specific for an amyloid-beta antigen associated with AD, wherein the PEG comprises a bifunctional molecule comprising a carboxy terminal and amine terminal, the carboxy terminal being connected to an amine group on the nanoparticles and an amine terminal being connected to the antibody as follows:

CeO₂—

NHCO—

[CH₂CH₂O]_n—

CH₂CH₂NH-antibody.

10. The composition of claim 9, contained in a manufactured medication biologically acceptable for administration to a patient suffering from AD.

11. A method of treatment for Alzheimer'"'"'s disease, the method comprising administering the composition of claim 9 to a patient suffering from AD.